RedHill Biopharma is an emerging Israeli
biopharmaceutical company focused primarily on the development and acquisition
of late clinical-stage, proprietary, orally-administered drugs for the
treatment of inflammatory and gastrointestinal diseases, including
gastrointestinal cancers. The company’s product pipeline currently features a
host of drug candidates in various stages of advanced clinical development
aimed at relieving suffering and saving lives. RedHill’s drugs are,
potentially, of lower cost and faster to market than other new chemical
entities under development, which could point to an exciting upcoming year for
the company.
Since its formation in 2009, RedHill has worked
towards addressing several disease targets, thus providing the company with a
built-in risk diversification. Current drug candidates in the company’s
pipeline include treatments to address helicobacter pylori infection, which
affects an estimated two-thirds of the world’s population, Crohn’s disease,
multiple sclerosis, Gastroenteritis and Gastritis, solid tumors, pancreatic
cancer, migraines and hypertension. The company’s experienced management team,
board of directors and advisory board, which are based in Israel, the U.S.,
Canada and Europe, come with a successful track record of bringing patented
drugs, such as those currently held by RedHill, to the market.
The company’s products currently in clinical
development include the following: RHB-105, which is an oral combination
therapy for the treatment of h. pylori infection currently under development in
its first Phase III trial; RHB-104, which is an oral combination therapy for
the treatment of Crohn’s disease under development in its first Phase
III trial, in addition to a Phase IIa study for the treatment of multiple
sclerosis; RHB-106, which is an encapsulated formulation for bowel preparation
currently licensed to Salix Pharmaceuticals Ltd.; BEKINDA™ (RHB-102), which is
a once-daily oral pill formulation currently in a Phase III study in the U.S.
for acute gastroenteritis and gastritis, in addition to having been submitted
for European marketing in December 2014 for the treatment of chemotherapy and
radiotherapy-induced nausea and vomiting; MESUPRON®, which is a Phase II-stage
uPA inhibitor targeting gastrointestinal and other solid tumor cancers; RP101,
which is currently under review for future development to target pancreatic and
other gastrointestinal cancers; RIZAPORT™ (RHB-103), which is an oral thin film
formulation for the treatment of acute migraines with a U.S. NDA under review
by the FDA; and RHB-101, which is a once-daily pill formulation of the cardio
drug carvedilol designed to treat hypertension and congestive heart failure.
The company’s outlook for the coming months
rests on the advancement and approval of various clinical trials and marketing
applications. With three ongoing Phase III programs, in addition to two
products with three pending marketing applications, the company is looking to
the future for more developments in order to help address unmet medical needs
around the planet. According to RedHill’s CEO, Dror Ben-Asher, “Heading into
2015, our pipeline is well balanced… We are looking forward to important
development and regulatory milestones throughout the year.”
For more information, visit www.redhillbio.com
About
MissionIR
MissionIR is committed to connecting the
investment community with companies that have great potential and a strong
dedication to building shareholder value. We know our reputation is based on
the integrity of our clients and go to great lengths to ensure the companies
represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer
on the MissionIR website http://www.missionir.com/disclaimer.html
